 "Dr. Slawin is a recognized authority on prostate disease and in addition to numerous scientific articles and book chapters published on this topic, he co-edited the “Atlas of the Prostate, Third Edition” together with renowned prostate expert, Dr. Peter Scardino, Chairman of Surgery at Memorial Sloan Kettering Hospital in New York. In addition, he authored the chapter on Robotic Radical Prostatectomy, one of seventeen chapters contained within the text." Urology Program at Memorial Hermann-Texas Medical Center named One of Nation’s Best by U.S. News & World Report 
Memorial Hermann-Texas Medical Center earned distinction as one of the nation’s top hospitals in U.S. News & World Report’s “America’s Best Hospitals” issue, published July 21, 2008. After an absence of several years, Memorial Hermann-TMC returned to the rankings at number 39 in the country for its urology program in only the first year after it entered into a strategic partnership with the Vanguard Urologic Institute, led by Dr. Kevin Slawin, who was appointed Director of Urology at Memorial Hermann-TMC in May 2007. Read more Center for Screening, Prevention, Detection, Surveillance, and Minimally Invasive and Focal Therapy for Prostate Cancer
“We believe that ultrasensitive PSA can be used after robotic or open radical prostatectomy as an unbiased indicator of complete prostate removal. In our hands, patients who achieve a very low level of PSA by ultrasensitive assay (< 0.01 ng/mL) have a high likelihood of cure and may face future follow up visits with less anxiety about possible cancer recurrence” 
“Most patients who have undergone radical prostatectomy surgery for the treatment of prostate cancer, performed either robotically or through an open approach, are followed after surgery with PSA blood testing, typically beginning about six weeks after surgery. Using a standard PSA blood test, an undetectable PSA level reported to the lower limit of most assays (<0.1 ng/mL) has typically been accepted as indication that a patient is cancer-free, however up to 20 – 30% of patients who initially achieve this low level will go on to develop a rising PSA level indicative of prostate cancer recurrence at some future date. read more
|
Contact UsA U.S. "Top Doctor"Best Doctors in America 2001-present America's Top Doctors for Cancer and Urology 2006-present   Prostate Facts and ToolsFollow Me On TwitterVirtual LibraryPatient Login
|
"The Vanguard Center for Screening, Prevention, Detection, Surveillance, and Minimally Invasive and Focal Therapy for Prostate Cancer was developed specifically to bring to bear the entire body of knowledge with respect to these sequential issues during the decision making process between each patient and his physician, and to use the latest online Web-enabled nomograms and other tools, to help men make the best, most well-informed decisions that fits each man’s philosophy and goals with respect to his health and lifestyle"
AUA Ultrasensitive PSA (
